About Ardelyx Company
Ardelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.
Jim Cramer Likes This Oil Giant Up Almost 28% In A Year — 'It Has Room To Grow'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Caterpillar Inc. (NYSE:CAT). "The stock is not priced for any sort of great growth, and yet I think that because of all the infra
Ardelyx Announced The Publication Of Results From The T3MPO-3 Long-term Open-label Safety Trial Of Ibsrela (Tenapanor) For Irritable Bowel Syndrome With Constipation In The Journal Of Neurogastroenterology And Motility
Ardelyx Announced The Publication Of Results From The T3MPO-3 Long-term Open-label Safety Trial Of Ibsrela (Tenapanor) For Irritable Bowel Syndrome With Constipation In The Journal Of Neurogastroenter
Daily rights tracking | Get rid of the last “sell” rating! Microsoft's bullish ratio has risen sharply; “zero-date rights” have made a comeback, accounting for more than 50% of turnover
Recently, Microsoft's implied volatility has shown an upward trend. Overnight's bullish share soared to 70%, and bullish chips were hoarded by investors; Sea soared nearly 12% overnight, and options trading volume increased nearly fourfold compared to the daily average, accounting for 75.5%.